New chemotherapy for patients with advanced hepatocellular carcinoma: Pilot study of β-interferon and doxorubicin one-shot intra-arterial chemotherapy
| Autor: | Hirokazu Uyama, Hironobu Nakamura, Hiroaki Nagano, Takamichi Murakami, Morito Monden, Norio Hayashi, Hideji Nakamura |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
medicine.medical_specialty One shot Chemotherapy Hepatology business.industry medicine.medical_treatment Therapeutic effect medicine.disease Gastroenterology Infectious Diseases Hepatocellular carcinoma Internal medicine medicine Doxorubicin Liver function β interferon business Progressive disease medicine.drug |
| Zdroj: | Hepatology Research. 37:1018-1025 |
| ISSN: | 1872-034X 1386-6346 |
| Popis: | BACKGROUND Patients with advanced hepatocellular carcinoma (HCC) need an effective treatment modality because of the poor prognosis of the disease. From an in vitro study, beta-interferon (IFN-beta) has been reported to enhance the antiproliferative effects of doxorubicin on HCC cell lines. In the present study, we investigated the therapeutic effects of combined IFN-beta and doxorubicin intra-arterial injection therapy on patients with advanced HCC. METHODS IFN-beta (3 MIU) and doxorubicin (10 mg/bodyweight) were given by one-shot intra-arterial injection through an arterial port to patients with advanced HCC. One treatment course consisted of three intra-arterial injections per week for 4 weeks. Three courses were conducted and evaluation was done monthly. RESULTS Eleven patients with advanced HCC were treated with combined IFN-beta and doxorubicin. One patient enteredcomplete remission (CR), seven patients were evaluated as having stable disease (SD) and three as having progressive disease (PD). The mean overall survival was 10 months. The mean survival for CR and SD patients was 15 months, and that for PD patients was 6 months (P = 0.0464, log-rank test). Decrease of serum total bilirubin was observed for all patients. CONCLUSION Combined IFN-beta and doxorubicin intra-arterial therapy offers an effective chemotherapy option for patients with advanced HCC by improving liver function and having tolerable side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|